Clinical Trial: Treatment of Peripheral T-cell Lymphoma
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Randomized Controlled Multi-center Clinical Trial on Treatment of Peripheral T-cell Lymphoma With DGPT Regiment (Gemcitabine,Cisplatin,Prednisone ,Thalidomide )
Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of GDPT regiment (gemcitabine，cisplatin,Prednisone ,Thalidomide
) for patients with Peripheral T-cell lymphoma.
Detailed Summary:
Patients with Peripheral T-cell lymphoma usually have a bad prognosis. These patients cannot be treated successfully with the conventional chemotherapy of CHOP. The investigators have been proceeding this trial to evaluate the efficacy and safety of the combination chemotherapy regiment GDPT regiment (gemcitabine，cisplatin,Prednisone ,Thalidomide
) in the patients with Peripheral T-cell lymphoma.
Sponsor: Mingzhi Zhang
Current Primary Outcome: Progression-free Survival [ Time Frame: up to end of follow-up-phase (approximately 24 months) ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Response Rate [ Time Frame: every 6 weeks,up to completion of treatment(approximately 18 weeks ) ]21 days(3 weeks) for one cycle,Efficacy was evaluated every two cycles
- Overall Survival [ Time Frame: up to the date of death (approximately 5 years) ]
- Median Survival Time [ Time Frame: 24 months ]
Original Secondary Outcome: Same as current
Information By: Zhengzhou University
Dates:
Date Received: August 10, 2012
Date Started: August 2011
Date Completion:
Last Updated: August 10, 2016
Last Verified: August 2016
